13Sep/13

Gilead's (GILD) Sofosbuvir FDA Panel Review Date Set for October 25th – StreetInsider.com (subscription)

Gilead’s (GILD) Sofosbuvir FDA Panel Review Date Set for October 25th
StreetInsider.com (subscription)
manufactured by Gilead Sciences, Inc. (Nasdaq: GILD), with a proposed indication for the treatment of chronic hepatitis C infection, in combination with other agents in adult patients with genotypes 1 to 6 and/or adult patients awaiting liver

10Sep/13

Liver disease on the rise among sober people – San Francisco Chronicle


San Francisco Chronicle

Liver disease on the rise among sober people
San Francisco Chronicle
Dr. Edward “Will” Holt, a physician with Sutter Pacific Medical Foundation, is a specialist in gastroenterology, hepatology and liver transplantation. He directs the fatty liver disease project at California Pacific Medical Center, San Francisco
Galectin Therapeutics Receives US Patent for Potential Ground-Breaking MarketWatch

all 9 news articles »